Despite significant improvements in the treatment outcomes of clear cell renal cell carcinoma (RCC), advanced/metastatic papillary RCC continues to have limited treatment options and there is clearly an unmet need. However, it is hoped that an optimal first-line treatment for papillary RCC will be identified in the next few years through the use of molecular profiling to determine the kidney cancer subtype, and well-tolerated MET kinase inhibitors, such as savolitinib that are undergoing clinical development.

Read the review article here